Company: BLRX
Filing Date: 2025-03-31
Form Type: 20-F
Source: 0001178913-25-001123
Chunk: 129

Company: BioLineRx Ltd.
Filing Date: 2025-03-31
Form: 20-F
Item: Item 3
Chunk 129
---
 physics from the Hebrew University of Jerusalem. In addition, Dr. Schwartz holds a Ph. D.
from the Hebrew University of Jerusalem in the history and philosophy of science.

Rami Dar, MBA, has served
on our board of directors (as an external director, within the meaning of the Companies Law, until March 25, 2024) since July 2022 and
as a member of our Audit Committee and Compensation Committee since such time and has served as a member of our Investment Monitoring
Committee since July 2022. Mr. Dar has served as a board member of BetterSeeds Ltd. since November 2023 and served as a board member of
Nordia Springs since March 2020. From 2018 to 2023, Mr. Dar served as chairman of Novolog Ltd. (TLV: NVLG). From 2002 to 2019, Mr. Dar
served as Chief Executive Officer of Hazera Seeds Ltd. (formerly Hazera Genetics), a leading global seed company, and prior to that, from
1998 to 2002, served in various management positions at Teva Pharmaceuticals Ltd., including as Business Development Executive from 2001
to 2002, Chief Executive Officer of Teva Medical Ltd., from 1998 to 2001, and Chief Executive Officer of Teva Pharmaceuticals Ltd. Israel
from 1995 to 1998. Mr. Dar holds a B. A. degree in economics and philosophy and an M. A. degree in economics, both from the Hebrew
University of Jerusalem, Israel, and an Executive M. B. A. from Columbia University, New York, USA.

BJ Bormann, Ph. D., has
served on our board of directors since August 2013 and on our Compensation Committee since 2022. Dr. Bormann previously served as the
Vice President of Translational Science and Network Alliances at The Jackson Laboratory, a non-profit organization focused on the genetic
basis of disease. Dr. Bormann was previously the Chief Executive Officer of Supportive Therapeutics, LLC, a Boston-based company that
is developing two molecules for use in the supportive care of oncology patients. In the past several years Dr. Bormann has held executive
positions in several biotechnology companies including NanoMedical Systems (Austin, Texas), Harbour Antibodies (Rotterdam, The Netherlands)
and Pivot Pharmaceuticals (PVTF: OTC listed). Prior to these engagements,